These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 2546315)

  • 1. The relation between orthophosphate and pyrophosphate in normal subjects and in patients with urolithiasis.
    Conte A; Roca P; Genestar C; Grases F
    Urol Res; 1989; 17(3):173-5. PubMed ID: 2546315
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Orthophosphate and other phosphate compounds in relation to stone formation.
    Fleisch H
    Adv Exp Med Biol; 1978; 103():203-16. PubMed ID: 213950
    [No Abstract]   [Full Text] [Related]  

  • 3. Urinary pyrophosphate in normal subjects and in stone formers.
    O'Brien MM; Uhlemann I; McIntosh HW
    Can Med Assoc J; 1967 Jan; 96(2):100-3. PubMed ID: 4289320
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Estimation of 24-h excretion of some promotors and inhibitors of crystallization and degree of urine saturation with calcium oxalate in calcium urinary calculi].
    Boruczkowska A
    Pol Arch Med Wewn; 1994 Oct; 92(4):289-98. PubMed ID: 7854956
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Urinary pyrophosphate level in lithiasis. Results of clinical studies on orthophosphate prevention of recurrent lithiasis].
    Sommer-Tsilenis E; Fenner O; Kallistratos G; Timmermann A
    Munch Med Wochenschr; 1967 Sep; 109(38):1971-4. PubMed ID: 4297845
    [No Abstract]   [Full Text] [Related]  

  • 6. [Pyrophosphate levels of the urine in lithiasis].
    Sommer-Tsilenis E; Kallistratos G; Timmermann A
    Munch Med Wochenschr; 1967 Feb; 109(6):293-5. PubMed ID: 4298874
    [No Abstract]   [Full Text] [Related]  

  • 7. EFFECT OF ORTHOPHOSPHATE ON URINARY PYROPHOSPHATE EXCRETION AND THE PREVENTION OF UROLITHIASIS.
    FLEISCH H; BISAZ S; CARE AD
    Lancet; 1964 May; 1(7342):1065-7. PubMed ID: 14132605
    [No Abstract]   [Full Text] [Related]  

  • 8. Role of inhibitor deficiency in urolithiasis. I. Rationale of urinary magnesium, citrate, pyrophosphate and glycosaminoglycan determinations.
    Akinci M; Esen T; Koçak T; Ozsoy C; Tellaloğlu S
    Eur Urol; 1991; 19(3):240-3. PubMed ID: 1649759
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polyanionic inhibitors of calcium oxalate crystal agglomeration in urine.
    Scurr DS; Latif AB; Sergeant V; Robertson WG
    Proc Eur Dial Transplant Assoc; 1983; 20():440-4. PubMed ID: 6197713
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical studies on the recurrence of urolithiasis: (1). Influence of diet on urinary excretion of the stone forming constituents].
    Murayama T; Taguchi H
    Hinyokika Kiyo; 1987 Sep; 33(9):1321-30. PubMed ID: 3434487
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phosphate metabolism and renal calcium stone disease.
    Wikström B
    Scand J Urol Nephrol Suppl; 1981; 61():1-56. PubMed ID: 6274003
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Urinary pyrophosphate in patients with recurrent calcium urolithiasis and in healthy controls: a re-evaluation.
    Schwille PO; Rümenapf G; Wölfel G; Köhler R
    J Urol; 1988 Aug; 140(2):239-45. PubMed ID: 2840520
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sodium is neither a risk nor a protective factor in urolithiasis?
    Singh PP; Pendse AK; Hada P; Nagori PC; Rathore V; Dashora PK
    Urol Res; 1987; 15(2):105-8. PubMed ID: 3590427
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A biochemical basis for grouping of patients with urolithiasis.
    Tiselius HG; Almgård LE; Larsson L; Sörbo B
    Eur Urol; 1978; 4(4):241-9. PubMed ID: 668734
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Urinary excretion of inorganic pyrophosphate by normal subjects and patients with renal calculi in north-western India and the effect of diclofenac sodium upon urinary excretion of pyrophosphate in stone formers.
    Sharma S; Vaidyanathan S; Thind SK; Nath R
    Urol Int; 1992; 48(4):404-8. PubMed ID: 1329300
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Urinary supersaturation with calcium oxalate before and during orthophosphate therapy.
    Burdette DC; Thomas WC; Finlayson B
    J Urol; 1976 Apr; 115(4):418-22. PubMed ID: 1263318
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of urine on "in vitro" crystallization rate of calcium oxalate: determination of inhibitory activity by a [14C]oxalate technique.
    Ligabue A; Fini M; Robertson WG
    Clin Chim Acta; 1979 Oct; 98(1-2):39-46. PubMed ID: 227625
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [On the significance of the renal excretion of pyrophosphate].
    Gundlach G; Hoppe-Seyler GF; Dörr H; Bressel M
    Urologe; 1968; 7(1):56-61. PubMed ID: 4297581
    [No Abstract]   [Full Text] [Related]  

  • 19. [Biochemical and clinical aspects of pyrophosphate metabolism. 2. Studies of the mechanism of enhanced pyrophosphate excretion in urine following orthophosphate loading].
    Thielmann K; Schulze M; Siegmund S; Hoeppener HH
    Acta Biol Med Ger; 1969; 22(5):687-98. PubMed ID: 4313445
    [No Abstract]   [Full Text] [Related]  

  • 20. Inhibitory effect of pyrophosphate, citrate, magnesium and chondroitin sulphate in calcium oxalate urolithiasis.
    Grases F; Genestar C; Conte A; March P; Costa-Bauzá A
    Br J Urol; 1989 Sep; 64(3):235-7. PubMed ID: 2553195
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.